760 F.Supp.3d 152
D. Del.2024Background
- Kaneka Corporation sued Designs for Health, Inc. (DFH) and American River Nutrition LLC (ARN) in the District of Delaware for alleged infringement of U.S. Patent No. 7,829,080 (the '080 patent) relating to stabilized ubiquinol (reduced CoQ [10]) compositions for dietary supplements.
- The litigation focused on claims 5 (composition claim) and 15 (method of producing composition) of the '080 patent after Kaneka dropped claims related to a now-expired earlier patent.
- DFH manufactured and sold supplement products containing ubiquinol sourced from ARN (DuoQuinol), which Kaneka alleged infringed its patent.
- The case was bifurcated, and the instant opinion addresses only liability issues after a bench trial; damages will be tried separately.
- The central trial evidence involved chemical analysis of the accused products conducted by Kaneka’s expert, Dr. Myerson.
- Defendants argued noninfringement, invalidity (anticipation, obviousness, written description, § 101 eligibility), and contested willful and induced infringement on various factual and legal grounds.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Direct Infringement | Products meet all limitations of claims 5 & 15 via expert testing | Testing method unreliable; key limitations not met | Kaneka proved direct infringement |
| Induced Infringement | ARN induced DFH to infringe; knowledge/instruction sufficient | No evidence of intent or knowledge; attorney opinion not disclosed | No induced infringement by ARN |
| Willful Infringement | Defendants knew of patent, acted despite attorney advice | No direct evidence of intent; non-disclosure not enough | No willful infringement |
| § 101 Patent-Eligibility | Claimed ratios/compositions have significant utility; not just natural | Mere combination of natural products; no "marked difference" | Claims are patent-eligible |
| Anticipation/Obviousness | Prior art does not disclose all limitations/motivation to combine | Prior art, especially '044 patent, covers all material aspects | Claims not anticipated or obvious |
| Written Description (§112) | Specification shows possession and methods; no need to quantify impurities | No adequate description of CoQ[11] presence or testing | Written description requirement satisfied |
Key Cases Cited
- Alice Corp. Pty. Ltd. v. CLS Bank Int’l, 573 U.S. 208 (two-step test for § 101 patent-eligibility)
- Mayo Collaborative Servs. v. Prometheus Lab’ys, Inc., 566 U.S. 66 (framework for elimination of law of nature/abstract ideas)
- Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (natural products are not patentable unless markedly different)
- Diamond v. Chakrabarty, 447 U.S. 303 (genetically engineered organism patent-eligible due to marked differences)
- Phillips v. AWH Corp., 415 F.3d 1303 (en banc) (claims must be read in light of the specification)
- Microsoft Corp. v. I4I Ltd. P’ship, 564 U.S. 91 (clear and convincing standard for invalidity)
- SRI Int'l, Inc. v. Cisco Sys., Inc., 930 F.3d 1295 (anticipation requires disclosure of every claim limitation)
- Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc., 752 F.3d 967 (obviousness requires motivation and expectation of success)